Physician profile
John Mcnerney
NPI 1568469583
$12,929.56
in general payments reported to CMS, 2019-2025
39 companies · $3,041 in 2025
The $3,041 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,307 · 2020: $418 · 2021: $419 · 2022: $1,039 · 2023: $3,371 · 2024: $3,335 · 2025: $3,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,692 · Education: $54.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,691.90 |
| Education | $54.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,101.04 | 2019-2025 | |
| Janssen Biotech, INC. | $1,406.56 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,251.57 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $832.67 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $718.01 | 2019-2025 | Xifaxan, Trulance |
| Aimmune Therapeutics, INC. | $631.98 | 2024-2025 | Zenpep, Vowst |
| Madrigal Pharmaceuticals | $582.86 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $575.63 | 2022-2025 | |
| Celgene Corporation | $549.38 | 2022-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $459.76 | 2023-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $306.69 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $269.55 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $258.66 | 2024 | Epclusa, Livdelzi |
| Lilly USA, LLC | $255.15 | 2025 | Omvoh |
| Medtronic, INC. | $195.64 | 2023 | Signia, Pillcam |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mcnerney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.